In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Investors soured on the sector when Elevance, an insurer, handed in disappointing results and shared a downbeat outlook.

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

HSBC Global Research has upgraded Divi's Laboratories Ltd. from a ‘reduce’ to a ‘buy’ rating, citing strong growth potential ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The improved outlook comes after the company ... with a price target of $3,000. Analyst Robert Ford likes the company’s ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.